Bulimia Nervosa Clinical Trial
Official title:
Antiglutamatergic Treatment of Bulimia Nervosa and Body Dysmorphic Disorder: An Open-Label Trial of Memantine
Verified date | April 2015 |
Source | Mclean Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The primary objective of this 13-week clinical trial is to test the hypothesis that treatment with Memantine will significantly improve the symptoms of those suffering from either bulimia nervosa, purging type or suffering from body dysmorphic disorder.
Status | Completed |
Enrollment | 5 |
Est. completion date | May 2011 |
Est. primary completion date | May 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: Bulimia Nervosa - Participants must meet DSM-IV criteria for a current diagnosis of bulimia nervosa as determined by the Structured Clinical Interview for DSM-IV (SCID) and Eating Disorder Examination (EDE). - Participants must report an average of 3 or more binges and vomiting episodes per week in the 2-week period prior to the screening visit. - Male or Female between 18 and 65 years of age, inclusive. - Female participants must be: postmenopausal for at least one year, surgically sterile, or practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization, abstinence and agreeing to continue abstinence or to use one of the acceptable methods of contraception just enumerated should sexual activity commence) before entry and throughout the study; and have a negative serum pregnancy test at the screening visit. - Participants must have observed a designated washout period of at least seven days or a period equal to five half-lives of prohibited medications. - Participants must be able to take oral medication, adhere to the medication regimens, and be willing to return for regular visits. - Participants must be able and willing to read and comprehend written instructions and comprehend and complete all scales and questionnaires required by the protocol. - Participants must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. Inclusion Criteria: Body Dysmorphic Disorder Inclusion criteria for participants with body dysmorphic disorder are identical to those for bulimia nervosa above, with the following differences in the first two criteria: - Participants must meet DSM-IV criteria for a current diagnosis of body dysmorphic disorder as determined by the SCID. - Participants must exhibit a score of = 20 on the Body Dysmorphic Disorder Version of the Yale Brown Obsessive Compulsive Scale (BDD-YBOCS) at a score of = 5 on the first three items of the BDD-YBOCS, which are the items that assess the DSM-IV criteria for Body Dysmorphic Disorder. Exclusion Criteria for both Bulimia Nervosa and Body Dysmorphic Disorder: - Participants with a lifetime diagnosis of schizophrenia, other psychotic disorder, or bipolar disorder as defined by DSM-IV and supported by the SCID. - Participants with clinically significant current depression or who, in the investigators' judgment, might require intervention with either pharmacological or non-pharmacological therapy for major depressive disorder over the course of the study. - Participants judged clinically to be at suicidal or homicidal risk by the study physician. - Participants meeting DSM-IV criteria for any form of substance dependence or abuse (with the exception of nicotine or caffeine dependence) within 3 months prior to the screening visit. - Participants meeting DSM-IV criteria for anorexia nervosa within 3 months prior to the screening visit. - Participants with a current DSM-IV diagnosis of an organic mental disorder. - Participants who have begun to receive formal psychotherapy (cognitive-behavioral therapy, interpersonal therapy or self-guided cognitive-behavioral therapy) for bulimia nervosa within 6 months prior to the screening visit. - Participants who display a positive urine screen for drugs of abuse (phencyclidine, cocaine, amphetamines, tetrahydrocannabinol, and opiates) at the screening visit. - Participants who have previously received memantine for any reason. - Participants who have received an investigational medication within 30 days of the screening visit. - Participants who are pregnant or lactating. - Participants with a body mass index (BMI) less than 18.5 or greater than 35. - Participants who have abused ipecac as a method of purging within the past 2 years. - Participants who exhibit a serum potassium level of less than 3.0 mEq/L. - Participants with thyroid-stimulating hormone concentrations outside the range of 0.5-5.0 lU/mL. - Participants with clinically significant or unstable medical conditions - Participants who in the opinion of the investigator should not be enrolled in the study because of the precautions, warnings or contraindications sections of the prescribing information for memantine - Employees of the investigator, individuals with direct involvement in studies under the direction of the study investigators, as well as family members of the employees of the investigators. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | McLean Hospital | Belmont | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Mclean Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Binge Eating and Self-induced Vomiting Episodes | Number of self-reported binge eating and self-induced vomiting episodes during the week prior to the Baseline and Endpoint Visits. | Baseline to 12 weeks | No |
Primary | Ratings of Eating Pathology | Ratings obtained from the self-induced vomiting and laxative misuse sections of the Eating Disorder Examination. The scale asks participants to calculate discreet episodes of self-induced vomiting and laxative misuses over the period of four weeks. Generally, the value obtained is the number of occurrences. However, in cases where the number of occurrences was too great to be calculated, the number "777" was used. The scale is therefore open-ended, with higher numbers coinciding with a greater number of episodes. | Baseline to 12 weeks | No |
Primary | Clinical Global Impression Scale | Disorder severity is measured based on the Clinical Global Impression Scale. The scale ranges from 1 unit (Not at all ill) to 7 units (extremely ill). | Baseline to 12 weeks | No |
Primary | Body Dysmorphic Disorder Version of the Yale Brown Obsessive Compulsive Scale | The scale ranges from 0 to 91 units, with 0 representing the least ill and 91 representing the most ill. | Baseline to 12 weeks | No |
Primary | Brown Assessments of Belief Scale | The range for this scale is 0 to 28 units, with 0 representing the least ill and 28 representing the most ill. | Baseline to 12 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04174703 -
Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing
|
N/A | |
Terminated |
NCT04278755 -
Binge Eating & Birth Control
|
Phase 2 | |
Withdrawn |
NCT02978742 -
Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder
|
N/A | |
Withdrawn |
NCT00988481 -
Topiramate Augmentation in Bulimia Nervosa Partial Responders
|
Phase 4 | |
Completed |
NCT00184301 -
A Comparison Study of Treatments Given to Patients With Concurrent Eating Disorder and Personality Disorder.
|
N/A | |
Completed |
NCT00522769 -
Cognitive Behavioral Therapy to Treat Bulimia Nervosa in Adolescents
|
Phase 1/Phase 2 | |
Completed |
NCT00304187 -
Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa
|
Phase 2 | |
Recruiting |
NCT04409457 -
Self-Control in Bulimia Nervosa
|
N/A | |
Recruiting |
NCT05509257 -
Naltrexone Neuroimaging in Teens With Eating Disorders
|
Early Phase 1 | |
Recruiting |
NCT05937243 -
Identifying Effective Technological-based Augmentations to Enhance Outcomes From Self-help Cognitive Behavior Therapy for Binge Eating
|
N/A | |
Recruiting |
NCT05862389 -
Study on the Mechanism of Eating Disorder
|
||
Recruiting |
NCT05728021 -
Smartphone-based Aftercare for Inpatients With Bulimia Nervosa
|
N/A | |
Completed |
NCT03781921 -
The Neural Bases of Emotion Regulation in Bulimia Nervosa
|
||
Completed |
NCT02553824 -
FDA Approved Medication to Reduce Binge Eating and/or Purging
|
Phase 1 | |
Terminated |
NCT04041024 -
Decision-making and Risk-taking in Bulimia
|
N/A | |
Completed |
NCT04265131 -
Emotion Regulation in Eating Disorders: How Can Art Therapy Contribute to Treatment Outcome?
|
N/A | |
Recruiting |
NCT06431854 -
Evaluation of a New Treatment Program for Adolescents With Eating Disorders: MINERVA Program
|
N/A | |
Recruiting |
NCT02960152 -
Periodontal Impact of Eating Disorders (the PERIOED Study)
|
N/A | |
Completed |
NCT00916071 -
Association Between Attention Deficit Hyperactivity Disorder and Bulimia Nervosa in Outpatients With Eating Disorders
|
N/A | |
Terminated |
NCT00308776 -
Cholecystokinin for Reducing Binge Eating in People With Bulimia Nervosa
|
N/A |